Clinical trial
Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma
NCT00017264 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00017264 |
|---|---|
| Title | Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma |
| Official title | A Phase I Evaluation of the Safety and Pharmacokinetics of ABT-627 in Adults With Recurrent Malignant Gliomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | atrasentan hydrochloride |
| Start date | Jun 1, 2002 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 13, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: